Atlas Trials

Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma

Clinical trial NCT04689659 · COMPLETED

Trial details

NCT number
NCT04689659
Sponsor
Beijing Boren Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
T-cell Leukemia/LymphomaRefractory T Lymphoblastic Leukemia/LymphomaRelapse/Recurrence
Start date
2021-12-01
Primary completion
2024-04-03
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.